The Division of Rheumatology strives to understand more about gout through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
HORIZON #20234982 Christopher Striebich, MD, PhD | A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (pegloticase) Administered Every 4 Weeks Compared with KRYSTEXXA Administered Every 2 Weeks with Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants with Uncontrolled Refractory Gout (FORWARD II) |
| 303-724-7518 or 303-724-7512 |